Cisplatin, carboplatin shortages raise questions about impact on clinical trials
At least two small biotechs have halted clinical trials due to shortages of cisplatin and carboplatin amid ongoing supply issues for the chemotherapies commonly used in cancer care.
Earlier this month, Replimune told investors that it put a Phase II clinical trial on hold until supply of both drugs becomes available. The study is testing one of its oncolytic viruses in combination with the standard of care in patients with squamous cell carcinoma of the head and neck.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.